R. Dalferth , K. Schütz , J. Berger , S.Y. Graeber , A. Balázs , M.A. Mall , F. Stanke , P. Maier , S. Tamm , N. Alfeis , B. Tümmler , A.-M. Dittrich
{"title":"两个孩子的复杂等位基因p.l u467php纯合。Phe508del对eleexaftor /tezacaftor/ivacaftor的临床反应降低,但在鼻电位差测量上存在差异","authors":"R. Dalferth , K. Schütz , J. Berger , S.Y. Graeber , A. Balázs , M.A. Mall , F. Stanke , P. Maier , S. Tamm , N. Alfeis , B. Tümmler , A.-M. Dittrich","doi":"10.1016/j.jcf.2025.03.565","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>In vitro studies demonstrate that homozygosity for the complex allele p.Leu467Phe-p.Phe508del (L467F-F508del) is associated with failure to respond to Elexacaftor/Tezacaftor/Ivacaftor (ETI). The functional CFTR response in vivo in homozygous carriers of these mutations has not yet been investigated. We report clinical and functional responses towards ETI of two L467F-F508del homozygous children.</div></div><div><h3>Methods</h3><div>Both received functional assessments of CFTR responses via sweat chloride and nasal potential difference (nPD) measurements along with in vitro testing of responsiveness in primary nasal epithelial cell cultures before and during ETI and one child additionally during lumacaftor/ivacaftor (LUM/IVA) therapy.</div></div><div><h3>Results</h3><div>The diagnosis of CF was made in the 1st and 3rd year of life revealing F508del homozygosity in both cases. After initiation of LUM/IVA, no drop in sweat chloride was observed in either child. The girl was switched to ETI at the age of 11, and the boy at age 6 years. Lack of pronounced drop in sweat chloride after initiation of ETI in both children (- 18mmol/l to 85mmol/l and -15 mmol/l to 93 mmol/l, respectively) led to resequencing of CFTR, which revealed L467F homozygosity in both children. Both showed sub-par clinical responses with the girl experiencing continued decline in lung function and the boy demonstrating an above average number of pulmonary exacerbations. Both children received nPD measurements with and without ETI therapy, which showed discrepant responses. Whereas the boy did not have any activity-differences by nPD, the girl showed a sub-par, but notable response during ETI therapy. In vitro testing in nasal epithelial cell culture is pending.</div></div><div><h3>Conclusion</h3><div>The presence of L467F-F508del homozygosity does not lead uniformly abrogate CFTR's response towards modulation via ETI, but is associated with a significantly reduced response. Therefore further investigation of complex alleles on CFTR modulator responsiveness is important.</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Page S25"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"WS13.02Two children homozygous for the complex allele p.Leu467Phe-p.Phe508del with reduced clinical response to elexacaftor/tezacaftor/ivacaftor but differences in nasal potential difference measurement\",\"authors\":\"R. Dalferth , K. Schütz , J. Berger , S.Y. Graeber , A. Balázs , M.A. Mall , F. Stanke , P. Maier , S. Tamm , N. Alfeis , B. Tümmler , A.-M. Dittrich\",\"doi\":\"10.1016/j.jcf.2025.03.565\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>In vitro studies demonstrate that homozygosity for the complex allele p.Leu467Phe-p.Phe508del (L467F-F508del) is associated with failure to respond to Elexacaftor/Tezacaftor/Ivacaftor (ETI). The functional CFTR response in vivo in homozygous carriers of these mutations has not yet been investigated. We report clinical and functional responses towards ETI of two L467F-F508del homozygous children.</div></div><div><h3>Methods</h3><div>Both received functional assessments of CFTR responses via sweat chloride and nasal potential difference (nPD) measurements along with in vitro testing of responsiveness in primary nasal epithelial cell cultures before and during ETI and one child additionally during lumacaftor/ivacaftor (LUM/IVA) therapy.</div></div><div><h3>Results</h3><div>The diagnosis of CF was made in the 1st and 3rd year of life revealing F508del homozygosity in both cases. After initiation of LUM/IVA, no drop in sweat chloride was observed in either child. The girl was switched to ETI at the age of 11, and the boy at age 6 years. Lack of pronounced drop in sweat chloride after initiation of ETI in both children (- 18mmol/l to 85mmol/l and -15 mmol/l to 93 mmol/l, respectively) led to resequencing of CFTR, which revealed L467F homozygosity in both children. Both showed sub-par clinical responses with the girl experiencing continued decline in lung function and the boy demonstrating an above average number of pulmonary exacerbations. Both children received nPD measurements with and without ETI therapy, which showed discrepant responses. Whereas the boy did not have any activity-differences by nPD, the girl showed a sub-par, but notable response during ETI therapy. In vitro testing in nasal epithelial cell culture is pending.</div></div><div><h3>Conclusion</h3><div>The presence of L467F-F508del homozygosity does not lead uniformly abrogate CFTR's response towards modulation via ETI, but is associated with a significantly reduced response. Therefore further investigation of complex alleles on CFTR modulator responsiveness is important.</div></div>\",\"PeriodicalId\":15452,\"journal\":{\"name\":\"Journal of Cystic Fibrosis\",\"volume\":\"24 \",\"pages\":\"Page S25\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cystic Fibrosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1569199325006617\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325006617","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
WS13.02Two children homozygous for the complex allele p.Leu467Phe-p.Phe508del with reduced clinical response to elexacaftor/tezacaftor/ivacaftor but differences in nasal potential difference measurement
Objectives
In vitro studies demonstrate that homozygosity for the complex allele p.Leu467Phe-p.Phe508del (L467F-F508del) is associated with failure to respond to Elexacaftor/Tezacaftor/Ivacaftor (ETI). The functional CFTR response in vivo in homozygous carriers of these mutations has not yet been investigated. We report clinical and functional responses towards ETI of two L467F-F508del homozygous children.
Methods
Both received functional assessments of CFTR responses via sweat chloride and nasal potential difference (nPD) measurements along with in vitro testing of responsiveness in primary nasal epithelial cell cultures before and during ETI and one child additionally during lumacaftor/ivacaftor (LUM/IVA) therapy.
Results
The diagnosis of CF was made in the 1st and 3rd year of life revealing F508del homozygosity in both cases. After initiation of LUM/IVA, no drop in sweat chloride was observed in either child. The girl was switched to ETI at the age of 11, and the boy at age 6 years. Lack of pronounced drop in sweat chloride after initiation of ETI in both children (- 18mmol/l to 85mmol/l and -15 mmol/l to 93 mmol/l, respectively) led to resequencing of CFTR, which revealed L467F homozygosity in both children. Both showed sub-par clinical responses with the girl experiencing continued decline in lung function and the boy demonstrating an above average number of pulmonary exacerbations. Both children received nPD measurements with and without ETI therapy, which showed discrepant responses. Whereas the boy did not have any activity-differences by nPD, the girl showed a sub-par, but notable response during ETI therapy. In vitro testing in nasal epithelial cell culture is pending.
Conclusion
The presence of L467F-F508del homozygosity does not lead uniformly abrogate CFTR's response towards modulation via ETI, but is associated with a significantly reduced response. Therefore further investigation of complex alleles on CFTR modulator responsiveness is important.
期刊介绍:
The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.